The TOGETHER Trial Evaluates Fluvoxamine for COVID-19
www.pulmccm.org
Jon-Emile S. Kenny MD [@heart_lung] “In those years, truth was elusive – as was my own faith that I could recognize and contain it.” -Mary Oliver Previously, the very basic underpinnings of fluvoxamine as a pharmacological method to quell cytokine unruliness was outlined. In brief, fluvoxamine is a sigma-1-receptor [S1R] agonist – an effect that opposes inositol-requiring enzyme 1 alpha [IRE1]. Disruption of IRE1 activity has an anti-inflammatory-like effect because IRE1 is normally stimulated by pathogen fragments [e.g., lipopolysaccharide, viral motifs, etc.] and splices into activity x-box binding protein [XBP]. XBP, in turn, triggers the expression of tumour necrosis factor alpha [TNF-a], interleukin-6 [IL-6], and the like.
The TOGETHER Trial Evaluates Fluvoxamine for COVID-19
The TOGETHER Trial Evaluates Fluvoxamine for…
The TOGETHER Trial Evaluates Fluvoxamine for COVID-19
Jon-Emile S. Kenny MD [@heart_lung] “In those years, truth was elusive – as was my own faith that I could recognize and contain it.” -Mary Oliver Previously, the very basic underpinnings of fluvoxamine as a pharmacological method to quell cytokine unruliness was outlined. In brief, fluvoxamine is a sigma-1-receptor [S1R] agonist – an effect that opposes inositol-requiring enzyme 1 alpha [IRE1]. Disruption of IRE1 activity has an anti-inflammatory-like effect because IRE1 is normally stimulated by pathogen fragments [e.g., lipopolysaccharide, viral motifs, etc.] and splices into activity x-box binding protein [XBP]. XBP, in turn, triggers the expression of tumour necrosis factor alpha [TNF-a], interleukin-6 [IL-6], and the like.